- Dual GIP/GLP-1 receptor agonists, a novel class of anti-obesity drugs, are emerging as a transformative solution in managing obesity and related metabolic disorders due to their dual action on glucose regulation and appetite suppression. These therapies have demonstrated superior efficacy and tolerability over conventional monotherapies, driving increased clinical adoption
- The surging demand for Dual GIP/GLP-1 receptor agonists is largely attributed to the global obesity epidemic, with more than 650 million adults classified as obese. Rising healthcare awareness, patient preference for non-surgical interventions, and robust clinical outcomes are further accelerating market penetration, especially in developed regions
- North America dominated the dual GIP/ GLP-1 receptor agonists obesity drugs market with the largest revenue share of 45.6% in 2024, supported by a high prevalence of obesity, advanced healthcare infrastructure, early adoption of innovative treatments, and the presence of major players such as Eli Lilly and Novo Nordisk. The U.S. alone accounted for over 82% of the regional market, fueled by favorable reimbursement policies and increasing use of combination therapies in chronic disease management
- Asia-Pacific is expected to be the fastest growing region in the dual GIP/ GLP-1 receptor agonists obesity drugs market, driven by growing urbanization, increasing disposable incomes, and rising obesity rates in populous nations such as China, India, and Japan.
- The Tirzepatide-based drugs segment dominated the dual GIP/ GLP-1 receptor agonists obesity drugs market with a market share of 47.8% in 2024, owing to strong clinical results from trials such as SURMOUNT and SURPASS, FDA and EMA approvals, and widespread use in managing both obesity and type 2 diabetes. The drug’s ability to deliver >20% weight loss in clinical trials has made it a game-changer in the obesity treatment space
